Kala Pharmaceuticals has appointed life sciences industry veteran Howard Rosen as chairman of the board of directors.
Rosen has held several senior roles at major biotechs, including his current positions on the board of directors at AcelRX, Aldea, Entrega and PaxVax, where he is also chairman.
His non-board experience includes serving as president and CEO of Pearl Therapeutics, which was acquired by AstraZeneca last year in a deal worth up to $1.15bn, as well as a period as VP, commercial strategy at Gilead Sciences and president of Johnson & Johnson subsidiary ALZA Corporation.
Kala’s president and CEO Guillaume Pfefer commented on this rich experience when welcoming Rosen.
“Howard’s extensive track record of building and guiding successful companies will be extremely helpful to Kala at this critical juncture as we advance a rich pipeline of ophthalmology product candidates into clinical development,” said Pfefer, who joined the eyecare specialist from Sanofi in 2012.